| Identification | Back Directory | [Name]
EP-1013 | [CAS]
223568-55-6 | [Synonyms]
F 1013
EP-1013
Z-VD-FMK (mixture of isomers)
(3S)-5-Fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxopentanoic acid
Pentanoic acid, 5-fluoro-3-[[(2S)-3-methyl-1-oxo-2-[[(phenylmethoxy)carbonyl]amino]butyl]amino]-4-oxo-, (3S)- | [Molecular Formula]
C18H23FN2O6 | [MOL File]
223568-55-6.mol | [Molecular Weight]
382.38 |
| Chemical Properties | Back Directory | [Boiling point ]
639.8±55.0 °C(Predicted) | [density ]
1.258±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : ≥ 60 mg/mL (156.91 mM) | [form ]
Solid | [pka]
3.92±0.19(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes[1]. | [in vivo]
EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversal rate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function[1]. | [IC 50]
Caspase | [References]
[1] Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66. DOI:10.2337/db07-1452 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
|